Vytrus Biotech S.A [VYT] vs Oryzon Genomics S.A [ORY] Detailed Stock Comparison

Vytrus Biotech S.A.

BME
Loading...

Oryzon Genomics S.A.

BME
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Vytrus Biotech S.A. wins in 13 metrics, Oryzon Genomics S.A. wins in 4 metrics, with 0 ties. Vytrus Biotech S.A. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Vytrus Biotech S.A. Oryzon Genomics S.A. Better
P/E Ratio (TTM) 49.36 N/A N/A
Price-to-Book Ratio 19.87 1.85 Oryzon Genomics S.A.
Debt-to-Equity Ratio 12.03 15.07 Vytrus Biotech S.A.
PEG Ratio 32.43 55.92 Vytrus Biotech S.A.
EV/EBITDA 41.45 -37.27 Vytrus Biotech S.A.
Profit Margin (TTM) 29.89% -23.83% Vytrus Biotech S.A.
Operating Margin (TTM) 32.87% 53.04% Oryzon Genomics S.A.
EBITDA Margin (TTM) 32.87% 53.04% Oryzon Genomics S.A.
Return on Equity 32.92% -2.53% Vytrus Biotech S.A.
Return on Assets (TTM) 15.29% -2.81% Vytrus Biotech S.A.
Free Cash Flow (TTM) $1.22M $-13.40M Vytrus Biotech S.A.
1-Year Return 512.50% 2.95% Vytrus Biotech S.A.
Price-to-Sales Ratio (TTM) 14.93 20.26 Vytrus Biotech S.A.
Enterprise Value $140.61M $208.60M Oryzon Genomics S.A.
EV/Revenue Ratio 14.51 19.08 Vytrus Biotech S.A.
Revenue per Share (TTM) $1 $0 Vytrus Biotech S.A.
Earnings per Share (Diluted) $0.39 $-0.03 Vytrus Biotech S.A.
Beta (Stock Volatility) -0.14 0.44 Vytrus Biotech S.A.

Vytrus Biotech S.A. vs Oryzon Genomics S.A. Stock Performance Analysis

Loading Price Chart...

VYT
ORY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Vytrus Biotech S.A.1.82%11.05%29.80%115.38%206.25%134.73%
Oryzon Genomics S.A.-1.34%-3.13%0.72%-12.81%-12.81%-13.35%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Vytrus Biotech S.A.512.50%497.56%595.04%595.04%595.04%595.04%
Oryzon Genomics S.A.2.95%31.60%-21.41%-5.42%-21.41%-21.41%

Performance & Financial Health Analysis: Vytrus Biotech S.A. vs Oryzon Genomics S.A.

MetricVYTORY
Market Information
Market Cap i€144.69M€220.00M
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i15,974235,645
90 Day Avg. Volume i14,159275,214
Last Close€19.60€2.79
52 Week Range€3.04 - €20.60€2.51 - €4.02
% from 52W High-4.85%-30.60%
All-Time High€20.60 (Apr 14, 2026)€5.25 (Dec 14, 2015)
% from All-Time High-4.85%-46.86%
Growth Metrics
Quarterly Revenue Growth0.53%0.49%
Quarterly Earnings Growth1.85%N/A
Financial Health
Profit Margin (TTM) i0.30%-0.24%
Operating Margin (TTM) i0.33%0.53%
Return on Equity (TTM) i0.33%-0.03%
Debt to Equity (MRQ) i12.0315.07
Cash & Liquidity
Book Value per Share (MRQ)€0.97€1.52
Cash per Share (MRQ)€0.46€0.37
Operating Cash Flow (TTM) i€3.90M€-2,356,163
Levered Free Cash Flow (TTM) i€76,132€-11,863,420
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Vytrus Biotech S.A. vs Oryzon Genomics S.A.

MetricVYT (Apr 24, 2026)ORY (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i49.36N/A
Forward P/E i32.4355.92
PEG Ratio i32.4355.92
Price to Sales (TTM) i14.9320.26
Price to Book (MRQ) i19.871.85
Market Capitalization
Market Capitalization i€144.69M€220.00M
Enterprise Value i€140.61M€208.60M
Enterprise Value Metrics
Enterprise to Revenue i14.5119.08
Enterprise to EBITDA i41.45-37.27
Risk & Other Metrics
Beta i-0.140.44
Book Value per Share (MRQ) i€0.97€1.52

Financial Statements Comparison: Vytrus Biotech S.A. vs Oryzon Genomics S.A.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricVYT (2025)ORY (2025)
Revenue/Sales i8.37M0
Cost of Goods Sold i-457,321-10.65M
COGS % of Revenue i-5.5%-
Gross Profit i8.83M10.65M
Gross Margin i105.5%-
Research & Development iN/AN/A
Operating Income (EBIT) i3.18M-5.71M
Operating Margin i38.0%-
EBITDA i4.16M-4.81M
EBITDA Margin i49.7%-
Pre-Tax Income i3.13M-5.60M
Pre-Tax Income % of Revenue i37.3%-
Income Tax i229,300-2.99M
Income Tax % of Revenue i2.7%-
Net Income (Profit) i2.90M-2.61M
Profit Margin i34.6%-

Balance Sheet & Liquidity Metrics

MetricVYT (2025)ORY (2025)
Cash & Equivalents i3.38M28.35M
Total Current Assets i5.39M30.67M
Total Current Assets % of Revenue i64.4%-
Total Current Liabilities i1.78M15.77M
Total Current Liabilities % of Revenue i21.2%-
Long-Term Debt i1.54M3.08M
Long-Term Debt % of Revenue i18.4%-
Total Shareholders Equity i10.31M117.85M
Retained Earnings i2.90M-20.81M
Retained Earnings % of Revenue i34.6%-
Property, Plant & Equipment i773,3431.16M

Cash Flow Statement Comparison

MetricVYT (2025)ORY (2025)
Operating Cash Flow i2.38M-6.19M
Operating Cash Flow % of Revenue i28.4%-
Capital Expenditures i-1.01M-59,394
Free Cash Flow i1.22M-13.40M
FCF Margin i14.6%-
Debt Repayment i-645,777-11.37M
Common Stock Repurchase i-867,3740

Short Interest & Institutional Ownership Analysis

MetricVYTORY
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i7.52M77.51M
Float Shares iN/A60.52M
% Held by Insiders i64.89%21.27%
% Held by Institutions i0.35%0.75%
% Held by Public i34.76%77.98%

Dividend Analysis & Yield Comparison: Vytrus Biotech S.A. vs Oryzon Genomics S.A.

MetricVYTORY
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A